Korean Journal of Clinical Pharmacy (한국임상약학회지)

Korean College Of Clinical Pharmacy (한국임상약학회)
권호 표지
DOI QR코드

DOI QR Code

Analysis of the Prescription Patterns of Medications that List Suicide in Use Cautions using the HIRA Claims Data

건강보험청구데이터를 이용하여 사용상의 주의사항에 자살이 기재된 약물의 처방 양상 분석

  • Oh, Suin (School of Pharmacy, Sungkyunkwan University) ;
  • Park, Hyekyung (School of Pharmacy, Sungkyunkwan University)
  • 오수인 (성균관대학교 약학대학) ;
  • 박혜경 (성균관대학교 약학대학)
  • Received : 2019.01.02
  • Accepted : 2019.09.11
  • Published : 2019.09.30
Download PDF
⟨ Previous Next ⟩

Abstract

Objective: Suicide has recently become an important social problem. Thus, we analyzed prescription drugs that cause suicidal ideation. Methods: Of 156 drugs on the the Minister of Food and Drug Safty (MFDS) EZ-Drug site that had "suicide" listed as a side effect, 78 had "suicide" listed as a warning or contraindication; those 78 drugs were analyzed using data from the 2016 Health Insurance and Review and Assessment Services National Patient Sample (HIRA-NPS). Results: 51 "suicide risk" drugs was identified. Of all patients, 5.2% had received such drugs. The prescription rate was 0.8% of all prescriptions, accounting for 1.6% of all prescription days. From logistic regression analysis, the prescription rate for the drugs was approximately 1.1 times higher for women than for men. With regard to age, the prescription rate for patients 66 years and older was 15.5 times higher than those for patients 25-years and lower. With regard to medical departments, the prescription rates in psychiatry and dermatology departments were 8.1 times higher and 0.6 times lower than those in internal medicine departments, respectively. With regard to region, the prescription rates in Daegu and Jeju were 1.3 times higher and 0.79 times lower than those in Seoul, respectively. Conclusion: Drug-induced suicidal behavior is possible, and therefore efforts are needed to prevent it.

Keywords

References

  1. Statistics of causes of death in 2016. Available from http://www.kostat.go.kr/portal/korea/kor_nw/2/6/2/index.board?bmode=read&bSeq=&aSeq=363268&pageNo=1&rowNum=10&navCount=10&currPg=&sTarget=title&sTxt=. Accessed May 26, 2018.
  2. 36 people a day, 1 person every 40 minutes suicide country ... 13th year OECD 1st place. Available fromhttp://www.yonhapnews.co.kr/bulletin/2018/01/22/0200000000AKR20180122153500017.HTML. Accessed July 20, 2018.
  3. Korea's suicide rate is 25.8 per 100,000 people in 2016...No. 1 in the OECD despite the decline. Available from https://www.yna.co.kr/view/AKR 20181026111300017?input=1195m. Accessed October 29, 2018.
  4. Ministry of Health and Welfare. Suicide prevention national action plan, Available from https://policy.nl.go.kr/search/searchDetail.do?rec_key=UH1_00000121715927. Accessed September 24, 2018.
  5. Olfson M, Marcus SC, Shaffer D. Antidepressant drug therapy and suicide in severely depressed children and adults: A case-control study. Archives of General Psychiatry 2006;63(8):865-72. https://doi.org/10.1001/archpsyc.63.8.865
  6. Ministry of Food and Drug Safety. 2015-2018.6 Report status of abnormalities by substance (suicide, suicidal tendencies, suicide attempts), 2018. Available from http://www.akomnews.com/bbs/board.php?bo_table=news&wr_id=5420. Accessed September 24, 2018.
  7. Takeuchi T, Takenoshita S, Taka F, Nakao M, Nomura K. The relationship between psychotropic drug use and suicidal behavior in Japan: Japanese adverse drug event report. Pharmacopsychiatry 2017 Mar;50(2):69-73. https://doi.org/10.1055/s-0042-113468
  8. Bell GS, Mula M, Sander JW. Suicidality in people taking antiepileptic drugs: What is the evidence? CNS Drugs 2009;23(4):281-92. https://doi.org/10.2165/00023210-200923040-00002
  9. Ministry of Health and Welfare. Suicide prevention white paper, 2017;1-170.
  10. Bangs ME, Tauscher-Wisniewski S, Polzer J, et al. Meta-analysis of suicide-related behavior events in patients treated with atomoxetine. J Am Acad Child Adolesc Psychiatry 2008 Feb;47(2):209-18. https://doi.org/10.1097/chi.0b013e31815d88b2
  11. Beasley CM Jr, Ball SG, Nilsson ME, et al. Fluoxetine and adult suicidality revisited: an updated meta-analysis using expanded data sources from placebo-controlled trials. J Clin Psychopharmacol 2007 Dec;27(6):682-6. https://doi.org/10.1097/jcp.0b013e31815abf21
  12. Kolch M, Fegert JM. [Medical treatment of depression in hilderen and adolescents]. Prax Kinderpsychol Kinderpsychiatr 2007;56(3):224-33. https://doi.org/10.13109/prkk.2007.56.3.224
  13. Pedersen AG. Citalopram and suicidality in adult major depression and anxiety disorders. Nord J psychiatry 2006;60(5):392-9. https://doi.org/10.1080/08039480600937561
  14. Poole-Wilson PA, Kirwan BA, Voko Z, de Brouwer S, et al. Safety of nifedipine GITS in stable angina: the ACTION trial. Cardiocasc Drugs Ther 2006 Feb;20(1):45-54. https://doi.org/10.1007/s10557-006-6312-4
  15. Maglione M, Miotto K, Iguchi M, Hilton L, Shekelle P. Psychatric symptoms associated with ephedra use. Expert Opin Drug Saf 2005 Sep;4(5):879-84. https://doi.org/10.1517/14740338.4.5.879
  16. Wolf DV. Sucidality following black-box warning. J Am Acad Child Adolesc Psychiatry 2005 May; 44(5):405. https://doi.org/10.1097/01.chi.0000155316.39930.63
  17. Brent DA. Antidepressants and pediatric depression -- the risk of doing nothing. N Engl J Med 2004 Oct 14; 351(16):1598-601. https://doi.org/10.1056/NEJMp048228

Cited by

  1. 일반의약품과 전문의약품 의도적 음독 자살 시도자 특성 분석 연구 vol.28, pp.2, 2020, https://doi.org/10.22722/kjpm.2020.28.2.116